CASP1 and fibrolamellar hepatocellular carcinoma: Overall, our data suggest that inflammation occurs early in FLC larvae and that pharmacological inhibition of TNFα secretion and caspase-1 activity might be targets to treat inflammation and progression in FLC patients.